Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

08 May 2021: Review Articles

A Review of Recent Research on the Role of MicroRNAs in Renal Cancer

Longfei Yang 1ABCDE , Xiaofeng Zou 2G , Junrong Zou 3D , Guoxi Zhang 2FG*

DOI: 10.12659/MSM.930639

Med Sci Monit 2021; 27:e930639

Authors information Article notes Copyright and License information

Table 1 miRNAs act as tumor suppressors in renal cancer. A summary of miRNAs name, specimen types, targeted messenger RNAs, functions, and clinical application is provided.

MicroRNASpecimenBiological functionClinical applicationTargetPathwaysRef.
miR-122-5p and miR-206In serumliquid biopsy[]3
miR-144-5pIn vitroSuppress cell proliferation, migration and invasionDFSSDC3[]12
miR-384In vitroInhibit cell proliferation, colony formation and invasionAEG-1RAS signaling pathway[]14
miR-106a-5pIn vitro and in vivoInhibit tumor metastasisDiagnosis, potential therapeutic targetPAK5RAS signaling pathway[]15
miR-532-5pIn vitro and in vivoInhibit tumor growth and decrease expression of KRAS, NAP1L1, P-ERK and ETS1KRAS, NAP1L1 and ETS1MAPK signaling pathway[]16
miR-199aIn vitroSuppress cell proliferation, migration and invasionROCK1RAS signaling pathway[]17
miR-622In vitroSuppress cell migration and invasion and decrease levels of P-ERKCCL18MAPK signaling pathway[]18
miR-200bIn vitro and in vivoInhibit tumor metastasis and decrease levels of P-ERKLAMA4MAPK signaling pathway[]19
miR-363In vitro and in vivoSuppress cell proliferation, migration and invasion, decrease level of STAT3, JAK2, VEGF, p-STAT3/JAK2/ERK, PDGF-A/B, N-cadherin, vimentin and ZEB1GHR, S1PR1MAPK/VEGF signaling pathway[, ]20
miR-10a-5pIn vitroSuppresses cell proliferation, migration and invasion, reduce p-ERK1/2, AKT, FAK and SRCPotential therapeutic targetSKA1MAPK and AKT signaling pathway[]21
miR-149In vitroInhibit cell migration, invasion and proliferationFOXM1PI3K/AKT signaling pathway[]23
miR-320aIn vitro and in vivoReduce tumor growthOS, diagnosisFoxM1PI3K/AKT signaling pathway[]24
miR-338-3pIn vitroIncrease cell proliferation and invasionp-AKT and PI3KPI3K/AKT signaling pathway[]25
miR-15aIn vitroInhibit cell proliferation, invasion and induce apoptosis, decrease expression of P13K, p-AKT, mTOR, cyclin D1, cyclin E, Bax, c-Myc and MMP3eIF4EP13K/AKT/mTOR signaling pathway[]26
miR-488In vitro and in vivoReduce tumor growth and decrease expression of N-cadherin, vimentin, p-AKT, p-mTOR, and P13KPotential therapeutic targetHMGN5P13K/AKT/mTOR signaling pathway[]27
miR-520c-3p/ 372-3p/373-3pIn vitro and in vivoDecrease tumor growth, metastasis and increase the expression of E-cadherin and PTENSPOPPI3K/AKT signaling pathway[]28
miR-203In vitro and in vivoDecrease tumor growth, metastasis and increase the expression of E-cadherin, PTEN, p21 and p27PI3K/AKT signaling pathway[]29
miR-148aIn vitro and in vivoReduce tumor growth and decrease p-Akt/mTOR, improve sensitivity to TRAIL and cisplatinPotential therapeutic targetAKT2 and Rab14AKT signaling pathway[, ]30
miR-766-3pIn vitro and in vivoReduce tumor growth and decrease P-AKT and P-ERKOSSF2AKT and MAPK signaling pathway[]32
miR-375In vitroInhibits cell proliferation, migration and invasion, while induce cell apoptosisPDK1[]33
miR-100In vitroInhibit cell invasion, migration and increase autophagy, reduce expression of mTOR, MMP-2 and MMP-9, whereas improve level of LC3 and LC3-II/LC3-INOX4mTOR signaling pathway[]34
miR-205-5pIn vitro and in vivoRepress tumor growth, inhibit expression of p-PI3K/Akt/-mTOR, increase sensitivity of cell to sunitinib, paclitaxel, 5-FU and oxaliplatinOS, potential therapeutic targetVEGFAVEGFA and Pl3k/AKT signaling pathway[]36
miR-299In vitro and in vivoSuppress tumor growth and inhibit expression of vimentin and N-cadherinVEGFVEGF signaling pathway[]37
miR-218In vitro and in vivoDecreases the expression of VEGFA, p-PI3K/p-Akt/p-mTOR diminish tumor angiogenesisOSGAB2VEGFA and Pl3k/AKT/mTOR signaling pathway[]39
miR-125a-3pIn vitroInhibit the expression of VEGF and tube numbers formed by HUVECsOS, DFSVEGFVEGF signaling pathway[]122
miR-148b-3pin vitro and in vivoSuppress tumor growth, tube formation of HUVECs and inhibit expression of HIF-1a, VEGF-A, PDGF-BB, and PDGF-DFGF2VEGF signaling pathway[]41
miR-486-5pin vitroInhibit cell proliferation and induce apoptosis, decrease apoptosis resistance induced by CCL2TAK1TGF-β signaling pathway[]43
miR-328In vitroInhibit cell proliferationITGA5TGF-β signaling pathway[]44
miR-186In vitroInhibit cell proliferation, invasion and induce apoptosis, decrease level of p-IkBa and p-p65SENP1NF-κB signaling pathway[]46
miR-765In vitroSuppress tumor growth and inhibit expression of VEGFA and Ki67 and eliminate lipids accumulationPLP2Metabolic related mechanism[]48
miR-409-3pIn vitroDecrease cell extracellular acidification rate, ATP production and increased oxygen consumption ratePDK1Metabolic related mechanism[]50
miR-497-5pIn vitroInhibit cell proliferation, migration and increase apoptosisOSPD-L1Immunity related mechanism[]51
miR-216aIn vitro and in vivoReduce tumor growthTLR4Immunity related mechanism[]52
miR-211-5pIn vitro and in vivoDecrease tumor growth and metastasisDFS, potential therapeutic targetSNAI1EMT program[]58
miR-124/203In vitroInhibit cell proliferation and migrationZEB2EMT program[]59
miR-101-5pIn vitroInhibit cell proliferation, invasion and induce apoptosisslugEMT program[]60
miR-490-3pIn vitro and in vivoInhibit tumor growth and metastasis, decrease VM formationTR4[]61
miR-32-5pIn vitro and in vivoInhibit tumor metastasis and repress expression of TR4, HGF and p-MetTR4[]62
miR-451aIn vitroSuppresses cell migration and invasionPMM2[]121
miR-200a-3pIn vitro and in vivoSuppress tumor growthCBL[]54
miR-182-5pIn vitro and in vivoInhibit tumor growth and metastasis, increase expression of P53[]56
miR-376b-3pIn rcc tissuesPFS, diagnosis[]101
miR-9-5pIn rcc tissuesDiagnosis[]102
miR-10a-5p/ 10b-5p/106a-5p/142-5pIn rcc tissuesDiagnosis[]107
miR-1208In vitroInhibits cell proliferation and promote apoptosis, sensitizes cisplatin-induced apoptosis and TRAIL-induced apoptosisPotential therapeutic targetTBCK[]111
miR-99a-3pIn vitroInhibit cell proliferation and facilitate apoptosis, induce S phase arrest and increase sunitinib sensitivityPotential therapeutic targetRRM2[]112
miR-126In vitroDecrease cell migration and lactate production, inhibit expression of p-mTOR, and sensitize the cancer cells tocisplatin or X-ray treatmentPotential therapeutic targetSERPINE1mTOR signaling pathway[]113
miR-378a-5pIn vitroInhibit cell proliferation, migration, invasion and promote apoptosisOS[]119
miR-31-5pIn vitroSuppress cell proliferation, migration and invasionOSCDK1[]120
miR-22/24/99a/ 194/214/ 335/339/708Biomarker[]6
miRNAs – microRNAs; DFS – disease-free survival; SDC3 – syndecan-3; AEG – 1-astrocyte-elevated gene-1; RAS – rat sarcoma; PAK5 – p21-activated kinase 5; KRAS – Kirsten rat sarcoma viral oncogene; p-ERK – phosphorylate extracellular signal regulated kinase; ETS1 – E26 transformation-specific-1; MAPK – mitogen-activated protein kinases; ROCK1 – Rho-associated coiled-coil-forming protein kinase 1; CCL18/2 – C-C motif chemokine 18/2; LAMA4 – laminin subunit alpha-4; STAT3 – signal transducer and activator of transcription 3; JAK2 – Janus kinases 2; VEGF – vascular endothelial growth factor; PDGF – platelet-derived growth factor; ZEB1 – zinc finger E-box binding homeobox 1; GHR – growth hormone receptor; S1PR1 – sphingosine-1-phosphate receptor 1; AKT – protein kinase B; FAK – focal adhesion kinase; SKA1 – spindle and kinetochore-associated protein 1; FOXM1 – forkhead box M1; OS – overall survival; PI3K – phosphatidylinositol 3-kinase; mTOR – mammalian target of rapamycin; MMP3 – matrix metalloproteinase-3; eIF4E – eukaryotic initiation factor 4E; HMGN5 – high-mobility group nucleosome binding domain 5; PTEN – phosphatase and tensin homolog deleted on chromosome 10; SPOP – speckle-type POZ protein; TRAIL – tumor necrosis factor-related apoptosis inducing ligand; Rab14 – ras-related protein 14; SF2 – splicing factor 2; PDK1 – phosphoinositide-dependent kinase 1; NOX4 – NADPH oxidase 4; LC3 – microtubule-associated protein 1 light chain 3; GAB2 – GRB2-associated binding protein 2; HUVECs – human umbilical vein endothelial cells; FGF2 – fibroblast growth factor 2; TAK1 – TGF-beta-activated kinase 1; ITGA5 – integrin alpha5; SENP1 – sentrin specific peptidase1; PLP2 – proteolipid protein 2; PD-L1 – programmed death ligand 1; TLR4 – toll-like receptor 4; SNAI1 – snail family transcriptional repressor 1; TR4 – testicular nuclear receptor 4; VM – vasculogenic mimicry; HGF – hepatocyte growth factor; PMM2 – phosphomannomutase 2; CBL – casitas B-lineage lymphoma; PFS – progression-free survival; TBCK – TBC1-domain-containing kinase; RRM2 – ribonucleotide reductase regulatory subunit m2; SLC7A5 – solute carrier family 7 member 5; HIF1a/2a – hypoxia inducible factor 1a/2a; SERPINE1 – serine protease inhibitor clade E member 1.
Back to the Article

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750